Successful treatment of in-transit metastatic melanoma in a renal transplant patient with combination T-VEC/Imiquimod immunotherapy

Joel C. Sunshine, Jeffrey Sosman, Aneesha Shetty, Jennifer N. Choi*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

In the era of immunotherapy for cancer, solid organ transplant patients who go on to develop metastatic or locally advanced melanoma offer particularly difficult challenges. New approaches are needed for these patients. We present a case of in-transit metastatic melanoma in a renal transplant patient. The patient was initially managed with talimogene laherparepvec (T-VEC) injections alone with continued local progression. Addition of topical imiquimod 5% cream to intralesional T-VEC resulted in a rapid and dramatic response, with complete clearance of the cutaneous in-transit metastases and without any sign of organ rejection. In solid organ transplant patients who lack surgical options and are not eligible for treatment with a BRAF inhibitor, and for whom treatment with checkpoint inhibitors present risk of organ rejection, T-VEC either alone or in combination with topical imiquimod should be considered for patients with locally advanced disease. This combination should be a consideration, with close observation, in patients with a history of organ transplantation and immunosuppression.

Original languageEnglish (US)
Pages (from-to)149-152
Number of pages4
JournalJournal of Immunotherapy
Volume43
Issue number4
DOIs
StatePublished - May 1 2020

Keywords

  • immunotherapy combination
  • in-transit metastases
  • melanoma
  • transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Successful treatment of in-transit metastatic melanoma in a renal transplant patient with combination T-VEC/Imiquimod immunotherapy'. Together they form a unique fingerprint.

Cite this